Stockysis — AI-Powered Stock News & Sentiment Analysis

HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $130

Benzinga Newsdesk www.benzinga.com Positive 77.8%

Neg 0% Neu 0% Pos 77.8%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $47 to $130.

Comments

No comments yet. Be the first!